Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)
Clinical trial NCT03643549 · RECRUITING
Trial details
- NCT number
- NCT03643549
- Sponsor
- Haukeland University Hospital
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-30
- Primary completion
- 2026-12-30
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.